{"entity":{"id":"nct04634357","kind":"trial","name":"ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma","aka":[],"tldr":"A phase 1/2 trial of ET140203 T Cells in hepatoblastoma and hepatocellular carcinoma, run by Eureka Therapeutics Inc., now recruiting.","summary":"ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma is a phase 1/2 interventional study registered as NCT04634357 by Eureka Therapeutics Inc., with 12 participants planned, started 2022-07-19 and due to reach its primary completion in 2027-12-31. Interventions recorded: ET140203 T Cells.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04634357","url":"https://clinicaltrials.gov/study/NCT04634357"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hepatoblastoma","hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04634357","phase":"1/2","setting":"An Open-Label, Dose Escalation, Phase I/II Clinical Trial of ET140203 T Cells in Pediatric Subjects With Relapsed/Refractory Hepatoblastoma (HB), Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC)","sponsor":"Eureka Therapeutics Inc.","enrolled":12,"outcomes":[]},"route":"/trials/nct04634357/","neighbours":{"cancer":[{"id":"hepatoblastoma","kind":"cancer","name":"Hepatoblastoma","route":"/cancers/hepatoblastoma/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}]}}